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Introduction
The regulation of leukocytosis is a balance between the exit of leukocytes into the
periphery and the production of these cells in the bone marrow. Within this com-
partment systemic cytokine levels orchestrate a regulated response to peripheral sig-
nals, leading to leukocyte expansion through the action of colony-stimulating fac-
tors. At the molecular level this is translated into oligosaccharide-lectin interactions,
expression of cell adhesion molecules, balances between proteases and inhibitors,
and chemokine-mediated leukocyte recruitment to specific body compartments.1
Interference at any of these levels could represent a possible treatment for acute
inflammatory reactions such as shock syndromes.2
An often explored strategy is interference with balances between proteases and
inhibitors, for example, matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs).3,4 MMPs are named after their ability to degrade extra-
cellular matrix proteins, namely gelatinases (MMP-2/9), collagenases (MMP-1/8/13),
stromelysins (MMP-3/10/11) and others, but are also able to degrade cell-surface and
intracellular molecules.5 One particular MMP implicated in cell mobility in and out
of the bone marrow is MMP-9 or gelatinase B.5 MMP-9 is primarily produced by
neutrophils, which pre-store large quantities of proMMP-9 (zymogen) in their terti-
Lipopolysaccharides or endotoxins elicit an excessive host inflam-matory response and lead to life-threatening conditions such asendotoxemia and septic shock. Lipopolysaccharides trigger mobi-
lization and stimulation of leukocytes and exaggerated production of
pro-inflammatory molecules including cytokines and proteolytic
enzymes. Matrix metalloproteinase-9 (MMP-9) or gelatinase B, a pro-
tease stored in the tertiary granules of polymorphonuclear leukocytes,
has been implicated in such inflammatory reactions. Moreover, several
studies even pinpointed MMP-9 as a potential target molecule to count-
er excessive inflammation in endotoxemia. Whereas the early effect of
lipopolysaccharide-induced inflammation in vivo on the expression of
MMP-9 in various peripheral organs has been described, the effects on
the bone marrow and during late stage endotoxemia remain elusive. We
demonstrate that TIMP-free MMP-9 is a major factor in bone marrow
physiology and pathology. By using a mouse model for late-stage endo-
toxemia, we show that lipopolysaccharides elicited a depletion of neu-
trophil MMP-9 in the bone marrow and a shift of MMP-9 and MMP-9-
containing cells towards peripheral organs, a pattern which was prima-
rily associated with a relocation of CD11bhighGr-1high cells. In contrast,
analysis of the tissue inhibitors of metalloproteinases was in line with a
natural, systematic upregulation of TIMP-1, the main tissue inhibitor of
TIMP-free MMP-9, and a general shift toward control of matrix metal-
loproteinase activity by tissue inhibitors of metalloproteinases.
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ABSTRACT
ary granules (also called gelatinase granules) for swift
release upon encounter with an inflammatory stimulus.6
When released in the bone marrow, activated MMP-9
processes membrane-bound Kit-ligand into soluble Kit-lig-
and and thereby keeps progenitor cells locally and initiates
recruitment of “escaped” hematopoietic stem cells to their
proliferative niche.7 In the periphery, MMP-9 contributes
to the recruitment of bone marrow-derived neutrophils to
the site of an inflammatory stimulus.8 It is not, therefore,
surprising that studies involving mouse models for sepsis
show beneficial outcomes for MMP-9-deficient mice
and/or mice treated with MMP inhibitors.9-12
In the body, MMP proteolytic activity is kept in check by
natural tissue inhibitors of metalloproteinases (TIMPs).
While all four TIMPs (TIMP-1 to -4) have inhibitory activ-
ity on all MMPs, TIMP-1 preferentially binds to MMP-9
and TIMP-2 to MMP-2.13 A unique feature of TIMP-2 is
that it can initiate the formation of a MT1-MMP/TIMP-
2/proMMP-2 cell surface complex that aids the conversion
of the proMMP-2 zymogen into activated MMP-2.14,15
Similar to MMP-9, TIMP-1 is of importance in bone mar-
row physiology, in particular in the maintenance of
hematopoietic stem cell quiescence16 and leukocytosis.17,18
Lipopolysaccharides (LPS) or endotoxins are glycolipids
present in the outer membrane of Gram-negative bacteria,
and are released upon lysis of bacteria. In the body, LPS are
detected as an alarm signal by leukocytes, endothelial cells
and parenchymal cells through their LPS-receptor complex
composed of myeloid differentiation factor 2 (MD2) and
toll-like receptor 4 (TLR4), a process which is facilitated by
LPS-binding protein (LBP) and CD14.19 This interaction
triggers cytokine production, leukocyte activation and
inflammation,20 and excessive stimulation can lead to
simultaneous activation of multiple parallel cascades that
lead to adult respiratory distress syndrome and shock.21
In this study we used injection of LPS as an animal model
to study the mechanisms behind acute inflammation
(endotoxemia) caused by Gram-negative bacteria.
Whereas the early effects of LPS in vivo on the expression
of MMPs in various peripheral organs are known (Online
Supplementary Table S1), effects on bone marrow and dur-
ing late stages remain elusive. This is remarkable, given the
importance of MMP-9 in leukocytosis and hematopoietic
recovery.7,8 The aim of this study was to evaluate the
effects of endotoxemia on bone marrow gelatinases
(MMP-2 and MMP-9) and, in parallel, the effect on their
natural inhibitors. With the use of real-time polymerase
chain reaction (qPCR), gelatin zymography and flow
cytometry analysis, we demonstrated that endotoxemia
results in depletion of MMP-9 from the bone marrow. In
parallel, this MMP-9 shift is complemented by systematic
upregulation of TIMP-1. Finally, immunohistochemical
analysis confirmed the migration of MMP-9-containing
cells from the bone marrow to blood and peripheral
organs.
Methods
Mouse model of endotoxemia and sample collection
Endotoxemia was induced in female 8-week old C57BL/6 mice
by intraperitoneal (i.p.) injection of LPS (E. coli 0111:B4, Sigma
Aldrich, L4391) at a dose of 10 mg/kg.22 Control mice were inject-
ed with an equal volume of vehicle (pyrogen-free phosphate-
buffered saline, PBS; LPS level below 12.5 pg/mL). Twenty-four
hours after injection, mice were sacrificed and organs were col-
lected. Bone marrow cells were collected from femora by flushing
the medullary cavity with PBS. Blood samples were collected by
cardiac puncture with a heparin-coated needle and syringe, and
immediately processed by centrifugation (2000 g for 10 min at
4°C). The supernatant (plasma) was collected and stored for pro-
tein analysis and the cell pellet was immediately processed for
downstream analysis. Tissues were homogenized and proteins
extracted with a Precellys lysing kit (Bertin Technologies), as
described in the Online Supplementary Methods. All procedures
were conducted in accordance with protocols approved by the
local ethics committee (project number P201/2012, KU Leuven,
Belgium). 
Gelatin zymography
Protein levels of proMMP-9, MMP-9, multimeric MMP-9,
proMMP-2 and MMP-2 were determined by gelatin zymography
on affinity-purified samples, as previously described.23 and
detailed in the Online Supplementary Methods. Prior to zymography
analysis, the total protein content was determined using a stan-
dard Bradford assay (Bio-Rad).
RNA expression analysis
RNA was extracted and equal amounts of RNA were converted
to cDNA. qPCR was performed using TaqMan® fast universal
PCR master mix (Applied Biosystems), PrimeTime® predesigned
qPCR assays (IDT) and a 7500 Fast Real-Time PCR System
(Applied Biosystems). Details, including primer specifications, are
provided in the Online Supplementary Methods. The housekeeping
gene Tbpwas used as a calibrator for the relative quantification of
gene expression. Normalization for Tbp and calculation of the rel-
ative expression was performed using the ΔΔCT method.24
Immunohistochemistry
Femora were placed in 6% formaldehyde (1 day), decalcified in
7% formic acid (2 days) and embedded in paraffin. Paraffin-
embedded bones were sliced into 5 µm sections and dried
overnight at 50°C. For immunohistochemical staining the
EnVisionTM FLEX kit (DAKO) was used. Goat anti-mouse MMP-
9 (R&D Systems) was used as the primary antibody. A detailed
protocol is provided in the Online Supplementary Methods.
Flow cytometry analysis
Spleens and bone marrow were passed through cell strainers
to obtain single cell suspensions. Red blood cells of spleen, bone
marrow and blood cell suspensions were lysed with 0.83%
NH4Cl. Cells were incubated with Fc-receptor-blocking antibod-
ies anti-CD16/anti-CD32 (BD Biosciences Pharmingen, San
Diego, CA, USA), Zombie aqua BV510 (dead cell staining)
(BioLegend, San Diego, CA, USA) and stained with anti-Gr1,
anti-F4/80, anti-CD11b, anti-CD3 or anti-CD19 (eBioscience,
San Diego, CA, USA). Cells were fixed and analyzed with a
FACS Fortessa flow cytometer. Data were processed with the
FlowJo software (Becton Dickinson Labware, Franklin Lakes, NJ,
USA). A detailed protocol is provided in the Online Supplementary
Methods.
Enzyme-linked immunosorbent assays and gelatin degra-
dation assays
TIMP-1 and TIMP-2 concentrations were determined using
mouse TIMP-1 (DY980) and TIMP-2 (DY6304-05) DuoSet
enzyme-linked immunosorbent assay (ELISA) kits (R&D
Systems). To determine the gelatinolytic activity we used a previ-
ously described gelatin degradation assay.25 A detailed protocol is
provided in the Online Supplementary Methods. 
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Statistical analysis
Data were analyzed using GraphPad Prism 7 software and are
expressed as mean ± standard error of mean (SEM). Differences
were determined using a Mann-Whitney test. Data were collected
and confirmed over a course of five independent experiments
with experimental groups ranging from two to six animals.
Results
The bone marrow compartment contains considerable
levels of MMP-9 RNA and protein
Publicly available mRNA expression data26 of human and
mouse tissues reveal that gene expression levels of MMP-9
are highest in bone and bone marrow of humans and mice
(Figure 1A). We, therefore, first evaluated the baseline lev-
els of MMP-9 protein in bone marrow, spleen, lungs, liver
and plasma by using gelatin zymography. The main source
of MMP-9 (here a combination of high-molecular weight
proMMP-9 and MMP-9) was indeed the bone marrow
(Figure 1B and Online Supplementary Figure S1), with bone
marrow MMP-9 representing over 0.1% of the total bone
marrow protein. Mean MMP-9 protein levels in bone mar-
row, spleen, lungs, liver and plasma were respectively
1131±212.8 ng/mg protein, 168.4±29.8 ng/mg protein,
49.1±4.9 ng/mg protein, 2.12±0.26 ng/mg protein and
0.6±0.09 ng/mg protein (mean±SEM, n = 5-10).
Endotoxemia results in a shift of the Mmp2/9 and
Timp1/2/3 expression pattern
Acute inflammation was induced by i.p. injection of
endotoxin. To follow hematologic changes during late
stages, samples were collected from bone marrow, blood
and spleen 24 h after LPS/PBS injection. Liver and lungs,
two organs prone to dysfunction during endotoxemia and
sepsis syndromes were also collected.27 Analysis of RNA
expression of Mmp9, Mmp2, Timp1, Timp2, Timp3 and
Timp4 in these tissues revealed a shift in the expression pat-
tern of both gelatinases and TIMPs (Figure 2). In the bone
marrow, the basal expression level of Mmp9 RNA was
reduced by endotoxemia, while Mmp9 expression in liver
and lungs increased significantly. In blood cells a trend
toward increased Mmp9 expression was seen, while Mmp9
mRNA levels in the spleen remained unaltered.
Interestingly, although the effect of endotoxemia on Mmp2
mRNA was less pronounced, it generally was opposing the
expression pattern of Mmp9. Steady-state Mmp2 mRNA
levels were increased in the bone marrow upon induction
of endotoxemia, while expression in the spleen and lungs
was decreased. While basal Timp1 expression was low,
endotoxin triggered a considerable systematic induction.
For Timp2 the opposite effect occurred, namely, a general
downregulation. A significant alteration in Timp3 expres-
sion was found in bone marrow (upregulation) and liver
(downregulation) while Timp4 expression remained low
and unaltered. All four TIMPs are thus differently regulated
in response to LPS.
Endotoxemia shifts MMP-9 from bone marrow to 
the circulation and peripheral organs
Biological samples contain complex mixtures of forms of
MMP-2 and MMP-9 proteins. A first level of complexity
lies in the fact that both proteases are produced as inactive
pro-enzymes, proMMP-2 and proMMP-9. Activation of
these pro-forms into active enzymes requires proteolytic
removal of the pro-peptide by other proteases (to form
MMP-2 and MMP-9) or chemical modification of the pro-
peptide cysteine thereby disturbing the pro-peptide/active
site interaction. These processes are fine-tuned and require
a local environment favoring MMP activation.5,28,29 A sec-
ond level of complexity involves the formation of high-
molecular weight disulfide linked MMP-9 multimers,
including MMP-9 trimers.30 Detailed analysis of these
forms provides better insights into the dynamics of pro-
tease activity and can be performed using gelatin zymogra-
phy analysis (Figure 3A).23 In Table 1, protein data for
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Figure 1. Organ-specific gene and protein expression of MMP-9. (A) Gene
expression of MMP-9 in human and mouse tissue based on publicly available
array data [human GeneAtlas U133A, gcrma and mouse GeneAtlas GNF1M,
gcrma dataset26]. Array data from different locations in one organ were pooled
in order to visualize the expression per organ (n = 2-28). (B) MMP-9 protein lev-
els in C57BL/6 mice as determined by gelatin zymography (n = 5-10). 
A
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MMP-2 and MMP-9 forms are provided for bone marrow,
liver, lungs, spleen and plasma from healthy mice and mice
with endotoxemia. As expected, basal levels of all MMP-9
forms were highest in the bone marrow followed by,
respectively, spleen, lungs, liver and plasma. Highest levels
of (pro)MMP-2 were detected in lungs, followed by spleen
and liver. MMP-2 was not detected in bone marrow, due to
an overflow effect of the high quantities of MMP-9.
Similarly, proteolytically activated MMP-9 could not be
detected in bone marrow due to the overflow effect of
proMMP-9. While proteolytic activation of MMP-9 proba-
bly occurs in this compartment, we could not detect this
due to the high levels of proMMP-9 within this compart-
ment. In plasma, MMP-2 levels were below the detection
limit but proMMP-2 was detected. Upon induction of
endotoxemia, drastic changes occurred in MMP-9 protein
levels. The most severe changes were observed in the bone
marrow, where protein levels of proMMP-9 and multimer-
ic MMP-9 dropped by approximately 90% or, respectively,
around 500 and 600 ng/mL (Table 1 and Figure 3B). This
major decrease of bone marrow (pro)MMP-9 coincided
with an increase of (pro)MMP-9 in liver and lungs, while
less pronounced effects were observed in the spleen.
Interestingly, mice with endotoxemia had a significant
decrease in the percentage of multimeric MMP-9 in spleen,
lungs and liver (Figure 3C). Indeed, downregulation of pro-
tein disulfide isomerase in sepsis was previously shown.31
While Mmp2 RNA expression analysis suggested an
opposing effect to MMP-9, this could not be confirmed at
the protein level, endorsing the existing notion that during
inflammation MMP-2 is less prone to major stimulation, in
comparison to the fine-tuned and controlled regulation of
MMP-9.32 Nevertheless, one should take into account that
non-secreted MMP-2 variants exist, which might shift the
balance between intracellular and secreted MMP-2.33
Interestingly, although the total (pro)MMP-2 content
remained similar, the percentage of proteolytically activat-
ed MMP-2 was increased in the lungs of endotoxemic mice
(Figure 3B,E). However, one needs to consider the possibil-
ity that proMMP-2 and proMMP-9 might also be activated
by other non-proteolytic mechanisms. Many non-prote-
olytic activation mechanisms of MMPs have been discov-
ered, for example, allosteric activation of proMMPs by
substrate binding or ligand binding34,35 and chemical modi-
fication of the propeptide cysteine by reactive
oxygen/nitrogen species such as peroxynitrite.28,29 To eval-
uate the possibility that LPS induce different MMP-9 mod-
ifications and charge variants, we evaluated the samples by
two-dimensional zymography.36 MMP-9 appeared as a
wide band of different charge variants, spanning almost
the full length of the isoelectric point (pI) gradient (Online
Supplementary Figure S2), likely caused by different post-
translational modifications. However, no major changes in
this pattern were observed in the LPS-stimulated samples.
With the limitations of the resolution and sensitivity of this
technique, we can conclude that no major charge modifi-
cations occurred upon induction of endotoxemia.
Systematic induction of TIMP-1 and reduction 
of TIMP-2
MMP activity is based on a balance between MMPs and
their natural inhibitors. We, therefore, analyzed TIMP-1
and TIMP-2 protein levels. Basal levels of TIMP-1 and
TIMP-2 were highest in the lungs (Table 2). Interestingly,
basal levels of TIMP-1 in bone marrow were low while
TIMP-2 was well represented. Next, LPS challenge resulted
in a systematic change in TIMP-1 protein levels (Figure
4A). In agreement with RNA expression data, TIMP-2 was
significantly decreased by LPS in bone marrow and spleen.
In sharp contrast, endotoxemia induced the production of
TIMP-1 in all organs, an effect which was most pro-
nounced in the bone marrow compartment. Taken togeth-
er, with a decrease in MMP-9 of approximately 90% and
an almost 8-fold increase of TIMP-1, the effect of endotox-
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Table 1. Levels of MMP-2 and MMP-9 forms detected in bone marrow, spleen, liver, lungs and plasma.
MMP-9 multimers proMMP-9 activated MMP-9 proMMP-2 MMP-2
Bone marrow
PBS 648±285 578± 378 ND ND ND
LPS 56.6±20.0 77.8± 39.4 ND ND ND
P **** **** ND ND ND
Spleen
PBS 54±9.1 59.3± 21.7 4.28±1.97 8.44±2.78 ND
LPS 42.4±6.6 65.0± 21.0 5.97±5.52 6.63±2.44 ND
P * ns ns ns ND
Lungs
PBS 26.4±7.4 20.9±4.3 9.06±1.10 16.44±2.51 5.64±2.70
LPS 40.7±17.8 43.7±13.0 15.99±4.65 15.11±2.87 9.53±2.64
P ns **** ** ns ns
Liver
PBS 1.1±0.24 1.03±0.39 0.21±0.18 1.53±0.46 0.27±0.02
LPS 2.3±0.4 3.09±0.84 0.59±0.19 1.47±0.65 0.30±0.04
P **** **** *** ns ns
Plasma
PBS 0.56±0.29 0.49±0.10 ND 3.22±0.48 ND
LPS 0.9±0.06 1.18±0.48 ND 4.68±0.62 ND
P ns * ND ns ND
Data are shown as mean±SD and are expressed as nanograms protease per milligram of tissue protein (ng/mg) as determined by gelatin zymography.  Control mice (adminis-
tered PBS) were statistically compared with mice given i.p. LPS injection. ND; no signal detected, ns; non-significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 as determined
by the Mann-Whitney test. Data were pooled from three independent experiments; n = 4-10.
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Figure 2. The effects of endotoxemia on Mmp9, Mmp2, Timp1, Timp2, Timp3 and Timp4 RNA expression. Relative RNA expression in bone marrow, spleen, lungs,
liver and blood cells of LPS-treated mice in comparison with the control group given PBS. Data were normalized for the housekeeping gene Tbp. Histograms represent
group medians and individual data points from single animals are shown by dots. *P<0.05, **P<0.01, as determined by the Mann-Whitney test (n = 3-6).
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Figure 3. Gelatin zymography analysis of the protein levels of MMP-9 and MMP-2 forms. (A) Representative gelatin zymography gels of bone marrow, spleen, lungs,
liver and plasma of mice treated with LPS versus control mice (PBS). Each lane represents the analysis of the sample from a single mouse (n = 3-4). Each sample
was spiked with an internal processing and loading control (MMP-9ΔHemOG – MMP-9 form lacking the C-terminal hemopexin and O-glycosylated domain) and each
gel has three lanes of recombinant MMP-9 standard protein (RS), including multimeric, monomeric and MMP-9 ΔHemOG proteins, to serve as a molecular weight
marker and standard (10, 5 and 3 pg). The loading quantity of the samples corresponded to, respectively, 0.4 mg (bone marrow), 2 mg (spleen), 4 mg (lungs), 60 µg
(liver) and 30 mg (plasma) of total protein. (B) Detailed analysis of protein levels of MMP-9 multimers, proMMP-9 monomers, activated MMP-9 monomers, proMMP-
2 and activated MMP-2. Protein quantity was expressed as nanograms of MMP in one milligram of total protein. (C) Percentages of multimeric MMP-9 out of total
MMP-9. (D) Percentages of proteolytically activated MMP-9 out of total MMP-9. (E) Percentages of proteolytically activated MMP-2. Histograms represent group medi-
ans and individual data points are shown by dots, each representing data from a single mouse. *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001, as determined
by the Mann-Whitney test.
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emia on the protease/inhibitor balance in the bone marrow
is substantial. Molar ratios of MMP-9/TIMP-1 indeed sug-
gest a basal proteolysis-favoring environment in the bone
marrow compartment, which decreases upon induction of
endotoxemia (Table 2). It does, however, need to be
emphasized that basal gelatinase-B in the bone marrow is
primarily in the proMMP-9 form. To confirm this effect,
net gelatinolytic activity in the bone marrow was meas-
ured using a gelatin degradation assay. As expected, bone
marrow samples contained net-proteolytic activity which
was significantly reduced upon treatment with LPS (Figure
4B). Moreover, by adding SB-3CT (an inhibitor of MMP-
2/MMP-9) and ElaV (an elastase inhibitor) we found that
bone marrow proteolysis, here represented by gelatinoly-
sis, is a combination of MMP-9 and elastase activity. MMP-
9 proteolysis accounted for approximately 30% of gelatin
proteolysis while elastase accounted for the remaining
70%. An interesting observation is that organs with high
levels of activated MMP-2/-9 (e.g. lungs and liver) also con-
tained higher levels of TIMPs. Although being paradoxical,
this observation might be explained by TIMP-assisted pro-
teolytic activation, as previously shown for MMP-2/TIMP-
2.14,15
Changes in MMP-9 levels correlate with neutrophil
migration patterns
Neutrophils are the main producers of MMP-9 and they
are unique because they do not produce TIMP-1.37,38 This
concept was elaborated in a pioneering study on angiogen-
esis in tumor biology,38 but seemingly also has relevance in
bone marrow physiology. We, therefore, hypothesized
that the TIMP-1/MMP-9 shift during endotoxemia might
be due to neutrophil mobilization into the circulation and
into peripheral organs. To investigate this, we performed
flow-cytometry analysis of bone marrow, spleen and
blood cells to study the migration pattern of T cells (CD3+),
B cells (CD19+), neutrophils (CD11b+Gr1+) and
macrophages (CD11b+F4/80+) in animals with and without
LPS injection (Figure 5). Indeed, in the bone marrow a sig-
nificant decrease (from 52% to 34%) in the CD11b+Gr-1+
population of neutrophils was seen with LPS (Figure 5A,B).
In addition, a shift of this population occurred towards the
peripheral blood circulation, from 7% to 34% CD11b+Gr-
1+ cells. Interestingly, endotoxemia also caused a reduction
in splenic macrophages (CD11b+F4/80+ cells: from 2% to
1%) and a decrease in circulating B cells (CD19+ cells: from
36% to 15%). In addition, we evaluated the RNA expres-
sion of myeloperoxidase (MPO) and neutrophil elastase
(ELANE), two molecules most abundantly expressed by
neutrophils and hence functioning as neutrophil markers,
in bone marrow, spleen, blood, liver and lungs. Overall, the
relative RNA expression of the neutrophil markers Mpo
and Elane followed a similar pattern as that for MMP-9,
except in the spleen, where a significant decrease was seen
in both Mpo and Elane expression upon induction of endo-
toxemia.
Immunohistochemical analysis of MMP-9
Next, we examined the tissue location of MMP-9 by
immunohistochemistry. In the bone marrow, total staining
for MMP-9 was markedly reduced in the animals adminis-
tered LPS (Figure 6A). In addition, the immunoreactive
staining was clearly confined to single cells which
appeared as polymorphonuclear cells. In control mice
(given PBS) these cells were diffusely found across the
bone marrow while in endotoxemic conditions more cells
were associated with the vasculature. In lungs (Figure 6B)
and liver (Figure 6C) the opposite phenomenon occurred.
While the baseline level of MMP-9-immunostained cells
was low and predominantly restricted to blood vessels,
LPS injection caused MMP-9-positive cells to migrate from
blood vessels into lung alveoli, bronchioles and liver
parenchyma. Again, staining was associated with poly-
mophonuclear cells. Spleen immunohistochemistry
revealed a similar staining pattern for both the PBS and LPS
conditions (Figure 6D). Generally, MMP-9-positive cells
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Table 2. Levels of TIMP-1 and TIMP-2 detected in bone marrow, spleen, liver and lungs.
TIMP-1 TIMP-2 MMP-9/TIMP-1 MMP-2/TIMP-2
Bone marrow
PBS 0.003±0.006 2.48±0.49 102167 ND
LPS 0.23±0.07 0.41±0.07 146 ND
P ** **
Spleen
PBS 0.15±0.06 1.61±0.62 196 1.53
LPS 0.98±0.41 0.98±0.23 28.9 1.97
P ** *
Lungs
PBS 4.12±1.09 8.84±1.29 3.42 0.73
LPS 17.53±4.56 8.77±2.02 1.43 0.82
P ** ns
Liver
PBS 1.32±0.53 0.41±0.41 0.44 1.28
LPS 4.20±2.66 0.83±0.82 0.36 0.62
P * ns
Data are shown as mean±SD and are expressed as nanogram of TIMP per milligram of tissue protein (ng/mg) as determined by ELISA. Control mice (PBS) were statistically com-
pared with mice given i.p. LPS injection. The two last columns represent the molar ratios of MMP-9/TIMP-1 and MMP-2/TIMP-2, calculated based on data in Table 1 and Table 2,
and taking into account the molecular weight of each of the proteins. Values higher than one represent an excess of MMPs compared to TIMPs. ND; no signal detected, ns; non-
significant, *P<0.05, **P<0.01 as determined by the Mann-Whitney test; n = 5-6.
were located in red pulp, while no staining was seen in
white pulp. In conclusion, immunohistochemical analysis
of bone marrow, spleen, liver and lung sections further
reinforced our data, showing decreased staining for MMP-
9 in bone marrow, increased staining in liver and lungs, and
no changes in the MMP-9 staining in spleen upon systemic
in vivo challenge with LPS. 
Discussion
Infection with Gram-negative bacteria accounts for about
60% of the bacterial infections causing sepsis, a disease
associated with considerable lethality, even with the most
sophisticated medical care.21 Previous studies suggest that
MMP inhibition may become a treatment for endotoxin
shock, although more in-depth preclinical work is neces-
sary. In our model we used LPS, a Gram-negative bacterial
component, to trigger endotoxemia and to study the distri-
bution patterns of the two key gelatinases (MMP-9 and
MMP-2) and their inhibitors (TIMPs). Since the time-depen-
dent increase of MMP-9 during early pathology (1-12 h after
induction of the syndrome) is well documented9,39,40 (Online
Supplementary Table S1), our study was focused at a later
stage of endotoxemia (24 h) and involved an in-depth analy-
sis thereof. Whereas the importance of MMP-9 in the devel-
opment of acute inflammation, such as sepsis syndrome, is
evident from the beneficial effects observed with the use of
MMP inhibitors,9-12 little is known about bone marrow
gelatinases (MMP-9 and MMP-2) or the effects on the bal-
ance between MMPs and their natural inhibitors. Here we
provide several new insights into this topic (Figure 7).
A first striking observation is the finding that MMP-9
accounts for more than 0.1% of total bone marrow pro-
tein, making MMP-9 an important factor in bone marrow
J. Vandooren et al.
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Figure 4. Systematic induction of TIMP-1 and reduced
bone marrow MMP gelatinolytic activity. (A) TIMP-1 and
TIMP-2 protein content in bone marrow, spleen, lungs
and liver of mice injected i.p. with LPS or control mice
(PBS injection) as determined by ELISA. Protein levels
detected by ELISA were corrected for the total protein
concentration and are presented as nanograms of TIMP
in one milligram of total protein. (B) Degradation of fluo-
rogenic gelatin by gelatinases present in bone marrow
samples from mice treated with LPS and control mice, in
the presence or absence of an inhibitor of MMP-2 and
MMP-9 (SB-3CT, 10 mM) or elastase inhibitor (ElaV, 10
mM). The velocity of the gelatin degradation reaction was
expressed as fluorescence units (FU) per minute and is
indicative of the net proteolytic activity present in the
samples. Inhibition percentages are shown. *P<0.05,
**P<0.01, as determined by the Mann-Whitney test.
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physiology and pathology, for example in hematopoiesis.
In addition, we show that during endotoxemia, the bone
marrow is the major source of MMP-9 and that this MMP-
9 is associated with polymorphonuclear cells. A limitation
of the present study is that the analysis was performed at
the single time-point of 24 h. Previous studies have shown
that a peak in plasma MMP-9 occurs as early as 1-12 h after
induction of sepsis39,40 and that MMP-9 is predominantly
associated with neutrophils6 and late-stage maturing neu-
trophils such as band cells and segmented cells, present in
the bone marrow.32,41 In our model of late endotoxemia (24
h), a significant shift in MMP-9 was still evident. In partic-
ular, we observed depletion of bone marrow MMP-9 and
significant increases in MMP-9 in lungs and liver, while the
spleen remained unaffected. This is in line with previous
studies showing that patients suffering from sepsis have
increased plasma levels of MMP-942 and that lungs and liver
are indeed two highly affected organs during endotoxemia
and sepsis syndromes.27 In parallel, we found that LPS
induced mobilization of MMP-9-containing cells into the
bloodstream. These cells predominantly migrated into
lungs and liver, where clear infiltrations of MMP-9-positive
cells were observed. We further confirmed this shift by
showing a similar pattern for Gr-1high cells, which have been
shown to contain large amounts of intracellular MMP-9.43
MMPs are indeed known to aid cell migration because of
their ability to degrade extracellular matrix molecules.5,8
This effect relies on direct proteolytic activity which is the
result of a fine-tuned balance of protease levels, protease
activation (the conversion of proMMP-9 into active MMP-
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Figure 5. MMP-9 levels relate with influx
or efflux of a population of Gr-1high neu-
trophils. (A) Bone marrow, spleen and
blood neutrophil content of mice not given
an LPS injection (PBS, top) and given an
LPS injection (bottom). Flow cytometry
plots represent the distribution of live
cells based on surface Gr-1 and CD11b
staining. (B) Analysis of the T-cell (CD3+),
B-cell (CD19+), neutrophil (CD11b+Gr1+)
and macrophage (CD11b+F4/80+) popula-
tions in bone marrow, spleen and blood as
determined by flow cytometry. (C) Relative
MPO and Elane RNA expression in bone
marrow, spleen, blood cells, liver and
lungs of mice treated with PBS (control) or
LPS. RNA expression data were normal-
ized for the housekeeping gene Tbp.
*P<0.05, **P<0.01, as determined by
the Mann-Whitney test.
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9 by proteolysis of the prodomain or chemical modification
of the pro-peptide cysteine) and the presence of inhibitors
(e.g. TIMP-1). An important new finding of our work is
that, although MMP-9 increases systemically after LPS chal-
lenge, a natural anti-proteolytic response occurs by system-
atically increasing TIMP-1. This is evident from both tissue
MMP-9/TIMP-1 ratios and proteolytic activity tests. In
addition, the relative expression of Timp1 also considerably
increased upon LPS challenge in almost all organs, including
the bone marrow. These findings allowed us to address two
questions: (i) whether inhibition of proteolysis by MMP-9
still has merit once acute inflammation has progressed (late-
stage) and (ii) whether the contribution of TIMP-1 is dis-
ease-promoting or disease-limiting. Most animal studies,
showing beneficial effects for MMP-9 inhibitors, were per-
formed with inhibitor injections immediately after the
induction of endotoxemia10-12 or in MMP-9 knock-out ani-
mals.8,9 In addition, higher serum levels of TIMP-1 have
been found in non-survivors compared to survivors of
severe sepsis.44 This confirms that the fine-tuned regulation
of MMPs, including their balance with TIMPs, is crucial for
tissue homeostasis.18 A good approach to the treatment of
acute inflammations might, therefore, rely on carefully
restoring this balance depending on the proteolytic state.
So far, the protease/anti-protease balance has been pre-
dominantly investigated in lungs and is key to normal lung
physiology. The most studied example in lungs is the elas-
tase/anti-elastase balance. This is exemplified by mouse
models in which both induction of elastase and mutations
of antitrypsin (elastase inhibitor) lead to emphysema.45 We
here show that endotoxemia also drastically affects the
lungs by inducing the accumulation of MMP-9-positive
cells. Nevertheless, this effect is counterbalanced by induc-
tion of TIMP-1. Indeed, it was previously suggested that the
pulmonary accumulation of neutrophils in sepsis is due to
shedding of platelet-derived surface-expressed CD40L by
MMP-9.46
Although TIMP-1 increases in bone marrow, most MMP-
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Figure 6. Immunohistochemical analysis of MMP-9 in bone marrow, lungs, liver and spleen. (A) MMP-9 immunohistochemical analysis of bone marrow from mice
with i.p. LPS injection and control mice (PBS). Arrowheads indicate immunoreactivity for MMP-9 in leukocytes associated with a blood vessel wall. (B) Lung MMP-9
immunohistochemical analysis. Increased infiltrations of MMP-9-positive cells from blood vessels (V) to surrounding alveoli and bronchioles (B) in lungs from mice
with endotoxemia (LPS), indicated by the arrowheads. The insert shows the typical polymorphonuclear nature of the infiltrating MMP-9-containing cells. (C) Liver
MMP-9 histology also shows clear infiltration of MMP-9-positive cells from blood vessels into the surrounding tissue. Infiltrating cells are indicated by arrowheads
and the magnification shows the typical polymorphonuclear nature of these cells. (D) Immunohistochemical analysis of the spleens of mice subjected to i.p. LPS or
control mice (PBS). MMP-9-positive cells were predominantly associated with the red pulp (RP) and not with white pulp (WP).
B
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9 (>99%) remains TIMP-free and thus potentially catalyti-
cally active. Indeed, neutrophils are unique in the fact that
they do not secrete TIMP-1.37,38 Moreover, this TIMP-free
MMP-9 was shown to have angiogenic capacity,38 in partic-
ular when neutrophils infiltrate peripheral tissue or tumor
microenvironments.47 In general, we show that bone mar-
row functioning relies on a combination of proteolysis by
MMP-9 and neutrophil elastase and that both activities are
reduced during late-stage endotoxemia. Previously it was
shown that neutrophil elastase can compensate for MMP-9
deficiency in a model of leukocyte infiltration in experi-
mental peritonitis.48 Neutrophil elastase is a serine protease
found in the azurophilic granules of neutrophils. In contrast
to MMP-9, neutrophil elastase knock-out mice have
impaired host defense against Gram-negative bacterial sep-
sis.49 Neutrophil elastase can, therefore, also be considered
as an important factor in endotoxin shock and requires fur-
ther investigation.
To date, the management of acute systemic inflamma-
tion, such as sepsis in patients, is mostly limited to sup-
portive care. Although targeting MMP-9 in these condi-
tions has been suggested, it has been shown that MMP-9
inhibition has a limited therapeutic time window.50
During late-stage endotoxin shock, the host responds
with systematic upregulation of TIMP-1 and shift in the
protease/anti-protease balance towards reduced proteoly-
sis. Together with reports showing higher levels of TIMP-
1 in non-survivors44 and the present data on profound
effects of LPS on MMP-9-laden neutrophils in the bone
marrow, successful treatment of sepsis with protease
inhibitors might first require detailed analysis of the pro-
tease/anti-protease balance in humans. Nevertheless, our
study provides new insights, techniques and data to
probe critical enzymes and inhibitors. In addition, it
shows the technical limitations encountered during in-
depth analysis of non-proteolytic MMP activation in a
biological setting. A future aim for the treatment of endo-
toxin shock might be the containment of neutrophils in
the bone marrow compartment for the purpose of pro-
hibiting collateral damage in the tissues of peripheral
organs. 
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Figure 7. Overview of the distribution
pattern of MMP-9/TIMP-1 and MMP-
2/TIMP-2 balances and MMP-9-positive
cells upon challenge with lipopolysac-
charide. Induction of endotoxemia
results in the migration of MMP-9-posi-
tive polymorphonuclear cells out of the
bone marrow to accumulate primarily in
lungs and liver. This release of MMP-9 is
meanwhile counteracted by a systematic
upregulation of TIMP-1. In contrast,
MMP-2 protein levels remain similar
while TIMP-2 is generally reduced. NE;
neutrophil elastase.
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